InsiderTrades.com logo
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.

AGN Insider Trading

Insider Ownership Percentage: 35.23%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Argenica Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Argenica Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Argenica Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 06/20/2022 01:03 PM ET

This chart shows the closing price history over time for AGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
The World's First "$20 Trillion Drug?"
From Behind the Markets   |   Ad
One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!
Get the name of the stock here >>>

Argenica Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2022Liz DallimoreInsiderIssued2,000,000A$0.54A$1,070,000.00
6/14/2022Liz DallimoreInsiderBuy10,916A$0.40A$4,366.40
See Full Table
The World's First "$20 Trillion Drug?"
From Behind the Markets   |   Ad
One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!
Get the name of the stock here >>>

SEC Filings (Institutional Ownership Changes) for Argenica Therapeutics (ASX:AGN)

6.77% of Argenica Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Read More on Argenica Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Who are the company insiders with the largest holdings of Argenica Therapeutics?

Argenica Therapeutics' top insider shareholders include:
  1. Liz Dallimore (Insider)
Learn More about top insider investors at Argenica Therapeutics.
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.